BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11516439)

  • 1. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat.
    Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
    Eur J Pharmacol; 2001 Jun; 421(3):R1-3. PubMed ID: 11516439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral sensitization to WIN55212.2 in rats pretreated with heroin.
    Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
    Brain Res; 2001 Apr; 898(1):178-80. PubMed ID: 11292463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist.
    Zhang Q; Ma P; Iszard M; Cole RB; Wang W; Wang G
    Drug Metab Dispos; 2002 Oct; 30(10):1077-86. PubMed ID: 12228183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.
    Hoffman AF; Oz M; Caulder T; Lupica CR
    J Neurosci; 2003 Jun; 23(12):4815-20. PubMed ID: 12832502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.
    Fattore L; Spano M; Melis V; Fadda P; Fratta W
    Br J Pharmacol; 2011 Aug; 163(7):1550-62. PubMed ID: 21518339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats.
    Li J; Daughters RS; Bullis C; Bengiamin R; Stucky MW; Brennan J; Simone DA
    Pain; 1999 May; 81(1-2):25-33. PubMed ID: 10353490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
    Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN
    Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.
    Aceto MD; Scates SM; Martin BB
    Eur J Pharmacol; 2001 Mar; 416(1-2):75-81. PubMed ID: 11282115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.
    Gomez DM; Everett TJ; Hamilton LR; Ranganath A; Cheer JF; Oleson EB
    Neuropharmacology; 2021 Jan; 182():108374. PubMed ID: 33115642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
    Ihenetu K; Molleman A; Parsons ME; Whelan CJ
    Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
    J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
    Tanda G; Pontieri FE; Di Chiara G
    Science; 1997 Jun; 276(5321):2048-50. PubMed ID: 9197269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large receptor reserve for cannabinoid actions in the central nervous system.
    Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
    J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
    Acquas E; Pisanu A; Marrocu P; Di Chiara G
    Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
    Rawls SM; Cabassa J; Geller EB; Adler MW
    J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
    Fattore L; Cossu G; Martellotta CM; Fratta W
    Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.
    Niederhoffer N; Szabo B
    Br J Pharmacol; 1999 Jan; 126(2):457-66. PubMed ID: 10077239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.
    Spano MS; Fattore L; Cossu G; Deiana S; Fadda P; Fratta W
    Br J Pharmacol; 2004 Oct; 143(3):343-50. PubMed ID: 15339858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats.
    Fattore L; Spano MS; Cossu G; Deiana S; Fratta W
    Eur J Neurosci; 2003 Apr; 17(8):1723-6. PubMed ID: 12752390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.